In Vivo. 2021 Sep-Oct;35(5):2875-2880. doi: 10.21873/invivo.12576.
ABSTRACT
BACKGROUND/AIM: To report the feasibility and oncological outcomes in breast cancer patients treated with a short hypofractionated radiotherapy schedule.
PATIENTS AND METHODS: We evaluated 380 breast cancer patients treated with ten daily fractions of radiotherapy up to 39 Gy on tumor bed. Primary endpoint was local relapse rate (LRR). Secondary endpoints were overall survival (OS) and metastasis-free survival (MFS).
RESULTS: The median follow up was 5.0 years. Two- and 5-year LRR rates were 0.2 and 2%, respectively. Two- and 5-year MFS rates were 96.1% and 90.5%, respectively. Two and 5-year OS rates were 97.4% and 95%, respectively.
CONCLUSION: This short schedule may represent an alternative option to standard mild hypofractionated radiotherapy in breast cancer patients due to its excellent feasibility and very low recurrence rate.
PM ID:34410981 | DOI:10.21873/invivo.12576
No comments:
Post a Comment